Stock Price & Analysis

Buy CPRX stock as strong earnings, positive analyst sentiment, and a $33.83 price target suggest upside potential. Selling is not recommended due to favorable fundamentals and growth prospects.

CPRX stock is predicted to reach $28.00 in 2025, driven by strong earnings growth and positive analyst sentiment. The stock is currently testing resistance levels and could break higher if momentum continues. However, insider selling activity may limit upside potential, with a more conservative target of $23.00.

The S1 support level for CPRX Stock is $20.57 ,The R1 resistant level for CPRX Stock is $23.81.

As of the end of day on 2025-03-24, the price of CPRX Stock was $25.8.

The target price for CPRX Stock according to analyst rating is 33.83, with the highest price target at 40.00 and the lowest at 31.00. Analysts have a Strong Buy rating on CPRX Stock overall.

The market cap of CPRX is $2.9B.

Catalyst Pharmaceuticals (CPRX) appears to be fairly valued based on current financial metrics and analyst sentiment. The stock has a P/E ratio of 15.91 and EV/EBITDA of 8.47, which are reasonable given its growth prospects. Recent revenue growth of 28% year-over-year and increasing net income margins support its valuation. Analysts maintain a "Buy" rating with a consensus price target of $33.83, indicating significant upside potential. While some insider selling has occurred, strong earnings performance and positive revenue guidance suggest continued growth. CPRX is not overvalued at current levels.

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.

CPRX stock is predicted to reach $45 by 2030, driven by its strong financial performance and expanding product portfolio. Analysts highlight the company's growing revenue and pipeline strength as key factors.

CPRX has a total of 167 employees.